Canagliflozin

A glucoside-derived SODIUM-GLUCOSE TRANSPORTER 2 inhibitor that stimulates urinary excretion of glucose by suppressing renal glucose reabsorption. It is used to manage BLOOD GLUCOSE levels in patients with TYPE 2 DIABETES.

Also Known As:

Networked: 966 relevant articles (133 outcomes, 353 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Mahaffey, Kenneth W: 59 articles (10/2022 - 08/2013)
2.	Perkovic, Vlado: 55 articles (10/2022 - 08/2013)
3.	Neal, Bruce: 54 articles (10/2022 - 08/2013)
4.	de Zeeuw, Dick: 41 articles (01/2022 - 08/2013)
5.	Meininger, Gary: 35 articles (01/2020 - 08/2013)
6.	Heerspink, Hiddo J L: 31 articles (10/2022 - 01/2017)
7.	Jardine, Meg J: 26 articles (01/2022 - 12/2017)
8.	Desai, Mehul: 26 articles (10/2019 - 08/2013)
9.	Shaw, Wayne: 23 articles (01/2022 - 08/2013)
10.	Matthews, David R: 21 articles (01/2022 - 09/2015)

Related Diseases

1.	Body Weight (Weight, Body) 12/01/2013 - "Treatment with canagliflozin for 12 weeks significantly improved glycaemic control and reduced body weight in Japanese patients with T2DM. " 03/01/2015 - "Canagliflozin improved glycaemic control, reduced body weight and systolic blood pressure, and was generally well tolerated in patients aged 55-80 years with T2DM over 104 weeks." 04/18/2014 - "Canagliflozin improved glycaemic control, body weight, and systolic BP, and was generally well tolerated in older patients with T2DM. " 04/01/2013 - "Canagliflozin treatment improved glycaemic control, reduced body weight and was generally well tolerated in subjects with T2DM inadequately controlled with diet and exercise." 03/14/2020 - "The aim of this study is to investigate the correlations between the changes of body weight and metabolic parameters during canagliflozin treatment. "
2.	Type 2 Diabetes Mellitus (MODY) 01/01/2013 - "Canagliflozin: a novel treatment option for type 2 diabetes." 10/10/2023 - "Remission effect of Canagliflozin in patients with newly diagnosed type 2 diabetes mellitus: a protocol for a multicenter, parallel-group, randomized, controlled, open-label trial." 01/01/2018 - "Clinical trials and real-world studies reported that canagliflozin (CANA) improved HbA1c, blood pressure (BP), and weight in patients with type 2 diabetes mellitus (T2DM). " 01/01/2016 - "Canagliflozin (CANA) has been shown to improve HbA1c, blood pressure (BP), and weight in patients with type 2 diabetes mellitus (T2DM) in clinical trials. " 01/01/2015 - "Safety and efficacy of canagliflozin in Japanese patients with type 2 diabetes mellitus: post hoc subgroup analyses according to body mass index in a 52-week open-label study."
3.	Heart Failure 04/04/2016 - "This trial has the potential to evaluate the clinical safety and efficacy of canagliflozin on heart failure. " 01/01/2022 - "Canagliflozin mitigates ferroptosis and ameliorates heart failure in rats with preserved ejection fraction." 01/01/2021 - "In this context, we designed a decentralized, patient-centered randomized clinical trial leveraging mobile technologies, rather than in-person site visits, to test the efficacy of 12 weeks of canagliflozin for the treatment of heart failure, regardless of ejection fraction or diabetes status, on the reduction of heart failure symptoms. " 01/01/2023 - "The CHIEF-HF (Canagliflozin Impact on Health Status, Quality of Life and Functional Status in Heart Failure) trial was designed as a double-blind, randomized, fully decentralized clinical trial (DCT) that identified, consented, treated, and followed participants without any in-person visits. " 01/01/2023 - "Recruitment Strategies of a Decentralized Randomized Placebo Controlled Clinical Trial: The Canagliflozin Impact on Health Status, Quality of Life and Functional Status in Heart Failure (CHIEF-HF) Trial."
4.	Insulin Resistance 01/01/2021 - "Finally, we showed that canagliflozin improved insulin resistance and hepatic steatosis in mice fed with a high-fat diet. " 01/01/2019 - "Hepatic insulin sensitivity improved with canagliflozin (P < 0.01), but not muscle or adipose tissue insulin sensitivity. " 12/01/2016 - "Glycaemic efficacy of canagliflozin is largely independent of baseline β-cell function or insulin sensitivity." 06/01/2023 - "Collectively, these results suggest that 1) adipose tissue insulin resistance is responsible for the weight changes with canagliflozin. " 02/10/2022 - "After multivariable regression analysis, age, visceral adipose tissue and CRP remained associated with increased insulin resistance, while canagliflozin treatment and higher NO level were associated with reduced insulin resistance. "
5.	Inflammation (Inflammations) 01/03/2023 - "Canagliflozin Attenuates Lipotoxicity in Cardiomyocytes by Inhibiting Inflammation and Ferroptosis through Activating AMPK Pathway." 07/01/2022 - "Our findings suggest that canagliflozin ameliorates the pathogenesis of NAFLD by regulating lipid metabolism and inhibiting inflammation, which may be associated with its promotion of autophagy." 07/01/2022 - "Canagliflozin Ameliorates Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism and Inhibiting Inflammation through Induction of Autophagy." 01/01/2018 - "Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice." 01/01/2021 - "Canagliflozin treatment significantly improved vascular function, lipid profile and inflammation and reduced liver injury. "

Related Drugs and Biologics

1.	Glucose (Dextrose)
2.	empagliflozin
3.	dapagliflozin
4.	Sodium-Glucose Transporter 2 Inhibitors
5.	Metformin (Glucophage)
6.	Sodium
7.	Insulin (Novolin)
8.	Blood Glucose (Blood Sugar)
9.	Hypoglycemic Agents (Hypoglycemics)
10.	glimepiride (Amarel)

Related Therapies and Procedures

1.	Glycemic Control
2.	Therapeutics
3.	Bariatric Surgery
4.	Aftercare (After-Treatment)
5.	Surgical Amputation (Amputations)